Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation. (APOLLO)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03242642 |
Recruitment Status :
Recruiting
First Posted : August 8, 2017
Last Update Posted : May 15, 2023
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Mitral Valve Regurgitation | Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 1350 participants |
Allocation: | Non-Randomized |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | Transcatheter Mitral Valve Replacement With the Medtronic Intrepid™ TMVR System in Patients With Severe Symptomatic Mitral Regurgitation - APOLLO Trial |
Actual Study Start Date : | October 23, 2017 |
Estimated Primary Completion Date : | October 2023 |
Estimated Study Completion Date : | October 2028 |
Arm | Intervention/treatment |
---|---|
Experimental: Primary Cohort- TMVR
Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
|
Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
mitral valve replacement Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement |
Experimental: Mitral Annular Calcification -TMVR
Treatment of mitral regurgitation with the Medtronic Transcatheter Mitral Valve Replacement System (TMVR)
|
Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR)
mitral valve replacement Device: Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) Medtronic Intrepid Transcatheter Mitral Valve Replacement System (TMVR) mitral valve replacement |
- Primary Cohort [ Time Frame: 1 year ]all-cause mortality or heart failure hospitalization post-30 days or KCCQ improvement < 10 composite
- MAC Cohort [ Time Frame: 1 year ]all-cause mortality and heart failure hospitalization composite
- all-cause mortality, disabling stroke, acute kidney injury, prolonged ventilation, deep wound infection, reoperation or reintervention, and major bleeding [ Time Frame: 30 days or hospital discharge (whichever is later) ]Composite
- Change in New York Heart Association Class [ Time Frame: 30 days ]change in NYHA Class
- Quality of Life Improvement [ Time Frame: 30 days (SF-12) and 3 months (KCCQ) ]measured by SF-12 and KCCQ
- Echocardiographic assessments of degree mitral valve regurgitation [ Time Frame: 1 year ]measured by echocardiography
- Cardiovascular hospitalizations [ Time Frame: 1 year ]cardiovascular hospitalizations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Moderate to severe or severe symptomatic mitral regurgitation
- Local site multidisciplinary heart team experienced in mitral valve therapies agrees that the subject is unsuitable for treatment with approved transcatheter repair or conventional mitral valve intervention
Exclusion Criteria:
- prior transcatheter mitral valve procedure with device currently implanted
- anatomic contraindications
- prohibitive mitral annular calcification
- left ventricular ejection fraction <30%
- need for emergent or urgent surgery
- hemodynamic instability

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03242642
Contact: Laura O'Brien | 7635289970 | rs.tmvrpivotaltrial@medtronic.com |

Study Chair: | Michael Mack, MD | Baylor Scott & White Hospital | |
Principal Investigator: | David Adams, MD | Icahn School of Medicine at Mount Sinai | |
Principal Investigator: | Martin Leon, MD | New York Presbyterian Hospital/Columbia University Medical Center |
Responsible Party: | Medtronic Cardiovascular |
ClinicalTrials.gov Identifier: | NCT03242642 |
Other Study ID Numbers: |
MDT17022TMV001 |
First Posted: | August 8, 2017 Key Record Dates |
Last Update Posted: | May 15, 2023 |
Last Verified: | May 2023 |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | Yes |
Device Product Not Approved or Cleared by U.S. FDA: | Yes |
Heart disease valve disease heart valve disease |
mitral regurgitation cardiovascular disease mitral insufficiency |
Mitral Valve Insufficiency Heart Valve Diseases Heart Diseases Cardiovascular Diseases |